These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15335295)

  • 1. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis.
    Fleischmann RM; Iqbal I; Stern RL
    Expert Opin Drug Saf; 2004 Sep; 3(5):391-403. PubMed ID: 15335295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological response modifiers in the management of rheumatoid arthritis.
    Louie SG; Park B; Yoon H
    Am J Health Syst Pharm; 2003 Feb; 60(4):346-55. PubMed ID: 12625216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.
    Fleishmann RM
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S35-41. PubMed ID: 14989428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The pulmonological manifestations of rheumatoid arthritis].
    Bernscherer G; Karabélyos C; Tarján Z
    Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
    Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
    Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
    Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic agents in rheumatoid arthritis: an update for managed care professionals.
    Agarwal SK
    J Manag Care Pharm; 2011; 17(9 Suppl B):S14-8. PubMed ID: 22073935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
    Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
    Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept in rheumatoid arthritis.
    Alldred A
    Expert Opin Pharmacother; 2001 Jul; 2(7):1137-48. PubMed ID: 11583065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of biological agents in the treatment of rheumatoid arthritis.
    Fan PT; Leong KH
    Ann Acad Med Singap; 2007 Feb; 36(2):128-34. PubMed ID: 17364080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-cytokine therapy for rheumatoid arthritis.
    Maini RN; Taylor PC
    Annu Rev Med; 2000; 51():207-29. PubMed ID: 10774461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.
    Moreland LW
    Pharmacoeconomics; 2004; 22(2 Suppl 1):39-53. PubMed ID: 15157003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects].
    Botsios C; Ostuni P; Sfriso P; Furlan A; Fiocco U; Sgarabotto D; Todesco S
    Reumatismo; 2003; 55(4):224-35. PubMed ID: 14872221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of new biologicals in the treatment of rheumatoid arthritis.
    Weaver AL
    Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii17-iii23. PubMed ID: 15150428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis.
    Inanc N; Direskeneli H
    Rheumatol Int; 2006 Nov; 27(1):67-71. PubMed ID: 16896990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.